571189-16-7

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-4-(6-NITROPYRIDIN-3-YL)PIPERAZINE is used as a building block for the preparation of heterocyclic compounds, specifically as a cdk-hdac double-channel inhibitor. These inhibitors play a crucial role in the development of novel therapeutic agents for various diseases, including cancer, by targeting and regulating the activity of specific cellular pathways.
In the context of cancer treatment, cdk-hdac double-channel inhibitors have the potential to disrupt the cell cycle and inhibit the growth of tumor cells, making them a valuable tool in the development of targeted cancer therapies. The use of 1-BOC-4-(6-NITROPYRIDIN-3-YL)PIPERAZINE in the synthesis of these inhibitors highlights its importance in the pharmaceutical industry and its contribution to the advancement of cancer research and treatment.

InChI:InChI=1/C14H20N4O4/c1-14(2,3)22-13(19)17-8-6-16(7-9-17)11-4-5-12(15-10-11)18(20)21/h4-5,10H,6-9H2,1-3H3

Upstream product

• 775288-71-6 1-(6-nitropyridin-3-yl)piperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 39856-50-3 5-bromo2-nitropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 110-85-0 piperazine 
• 311-28-4 tetra-(n-butyl)ammonium iodide 
• 1221726-34-6 1-(6-nitropyridin-3-yl)piperazine hydrochloride 
• 21717-96-4 2-amino-5-fluoropyridine 
• 779345-37-8 5-fluoro-2-nitro-pyridine 
• 52092-47-4 5-chloro-2-nitropyridine 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 571188-59-5 tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate 
• 1211441-98-3 (7-cyclopentyl-Ν,Ν-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo [2,3-d]pyrimidine-6-carboxamide) 
• 1374639-78-7 N,N‐dimethyl‐7‐cyclopentyl‐2‐{[5‐(4-tert-butoxycarbonylpiperazin‐1‐yl)pyridin‐2‐yl]amino}‐7H‐pyrrolo[2,3‐d]pyrimidine‐6‐carboxamide 
• 1374639-75-4 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate 
• 1402049-25-5 tert-butyl 4-(6-(2-(2-methoxy-4-(methoxycarbonyl)phenyl)-4-oxothiazolidin-3-yl)pyridin-3-yl)piperazine-1-carboxylate 
• 1615687-54-1 methyl 3-methoxy-4-(4-oxo-3-(5-(piperazin-1-yl)pyridin-2-yl)thiazolidin-2-yl)benzoate 
• 1615687-44-9 methyl 3-methoxy-4-(3-(5-(4-(4-methoxyphenylsulfonyl)piperazin-1-yl)pyridin-2-yl)-4-oxothiazolidin-2-yl)benzoate 
• 1615687-45-0 methyl 3-methoxy-4-(3-(5-(4-(4-nitrophenylsulfonyl)piperazin-1-yl)pyridin-2-yl)-4-oxothiazolidin-2-yl)benzoate 
• 1615687-46-1 methyl 4-(3-(5-(4-(mesitylsulfonyl)piperazin-1-yl)pyridin-2-yl)-4-oxothiazolidin-2-yl)-3-methoxybenzoate 
• 1615687-47-2 methyl 4-(3-(5-(4-(2,5-dichlorophenylsulfonyl)piperazin-1-yl)pyridin-2-yl)-4-oxothiazolidin-2-yl)-3-methoxybenzoate 
• 1615687-48-3 methyl 3-methoxy-4-(4-oxo-3-(5-(4-(phenylsulfonyl)piperazin-1-yl)pyridin-2-yl)thiazolidin-2-yl)benzoate 
• 1615687-49-4 methyl 4-(3-(5-(4-(4-fluorophenylsulfonyl)piperazin-1-yl)pyridin-2-yl)-4-oxothiazolidin-2-yl)-3-methoxybenzoate 
• 1615687-50-7 methyl 3-methoxy-4-(3-(5-(4-(3-methylbenzyl)piperazin-1-yl)pyridin-2-yl)-4-oxothiazolidin-2-yl)benzoate 
• 1615687-51-8 methyl 3-methoxy-4-(4-oxo-3-(5-(4-(3,4,5-trimethoxybenzyl)piperazin-1-yl)pyridin-2-yl)thiazolidin-2-yl)benzoate 

Relevant academic research and scientific papers

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma

Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play determinant roles in MM, but no remarkable progress has been obtained from clinical trials of CDK4/6 inhibitors for MM. To discover novel CDK6 inhibitors with better potency and high druggability, structure-based virtual screening was conducted to identify compound 10. Further chemical optimization afforded a better derivative, compound 32, which exhibited strong inhibition of CDK4/6 and showed high selectivity over 360+ kinases, including homologous CDKs. The in vivo evaluation demonstrated that compound 32 possessed low toxicity (LD50 > 10,000 mg/kg), favorable bioavailability (F% = 51%), high metabolic stability (t1/2 > 24 h) and strong anti-MM potency. In summary, we discovered a novel CDK4/6 inhibitor bearing favorable drug-like properties and offered a great candidate for MM preclinical studies.

Industrial preparation method 4 - (6 - amino-pyridin -3 -yl) piperazine -1 - carboxylic acid tert-butyl ester

The method adopts 4 - bromo 6 - nitropyridine and piperazine as a starting raw material to prepare high-purity -3 - (-1 -nitropyridine 5 -yl) piperazine -2 - carboxylic acid as a catalyst through nucleophilic substitution reaction in the presence of an organic solvent and water. 1 - (6 - aminopyrid -3 -yl) piperazine is prepared by using an acid as a catalyst in a mixed solvent of an alcohol organic solvent and water to obtain high-purity Boc (4 -aminopyridine 6 -1 -yl) piperazine-3 -carboxylic acid tert-butyl ester. Shallow color 4 - (6 - aminopyrid -3 -yl) piperazine -1 - carboxylic acid tert-butyl ester. The method is simple and convenient to operate, less in environmental pollution, high in yield, low in cost, good in product quality and more suitable for industrial production.

DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS

A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of FLT3 and its mutant forms and/or other protein kinases such as CDKs. The compounds have the general structure I:

CDK6/DYRK2 Double-target inhibitor as well as preparation method and application thereof

The present invention discloses a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. The invention also discloses a preparation method of the compound and application of the compound in prevention and/or treatment of cancers or tumor-related diseases, especially breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases. The compound provided by the invention is expected to be developed into a new generation of anti-cancer drugs.

Anti-cancer quinoxaline pyrimidinamine heterocyclic compound as well as preparation method and application thereof

The invention discloses an anti-cancer quinoxaline pyrimidinamine heterocyclic compound and a preparation method and application thereof, the structure of the compound is shown as a formula (S), and X is selected from C (O) or (CH2) n; n is 0 or 1; R1 is selected from hydrogen and C1-C8 alkyl; R2 is selected from hydrogen, C1-C8 alkyl, morpholine ring or-NR5R6, and R5 and R6 are selected from hydrogen and C1-C8 alkyl; R3 is selected from hydrogen, methoxyl and halogen; and R4 is selected from hydrogen, C1-C8 alkyl,-S (O) 2Me and-C (O) OC1-C3. The invention also discloses a preparation method and application of the compound.

Intermediate compound as well as preparation method and application thereof

The invention discloses an intermediate compound as well as a preparation method and application thereof. The synthesized intermediate compound is used for preparing targeted anti-cancer drugs, such as CDK4, CDK6, DYRK2 and other inhibitors, and is used for preventing and/or treating cancers or tumor related diseases including breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer and human glioma. The intermediate compound is simple in preparation condition, high in reaction yield and stable in performance.

Azaindole pyrimidinamine heterocyclic compound as well as preparation method and application thereof

The invention discloses an azaindole pyrimidinamine heterocyclic compound as well as a preparation method and application thereof. The compound is shown as a formula (S). The compound provided by the invention can inhibit malignant proliferation of cancers, has good treatment effect, low toxicity and good drug metabolism characteristics, is not easy to generate drug resistance, and can be used for preparing drugs for treating cancers or tumor-related diseases. The cancers or tumor-related diseases include multiple myeloma, leukemia, breast cancer, prostate cancer, lung cancer, liver cancer, gastric cancer, bone cancer, brain cancer, head and neck cancer, intestinal cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer and endometrial cancer.

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

CDK6 inhibitor of pyrimidine benzo six-membered ring mother nucleus as well as preparation method and application of CDK6 inhibitor

The invention discloses a CDK6 inhibitor of a pyrimidine benzo six-membered ring mother nucleus and a preparation method and application of the CDK6 inhibitor, the compound structure of the CDK6 inhibitor is shown as a formula (C), and A is selected from O, C (O) or-NR1; R1 is selected from hydrogen or C1-C8 alkyl; B is selected from O or C; X is selected from C, C (O) or-NR2; R2 is selected from hydrogen or C1-C8 alkyl; Y is selected from C (O) or (CH2) n; n is 0 or 1; and Z is selected from hydrogen, C1-C8 alkyl or-C (O) OC1-C3. The invention also discloses a preparation method and application of the compound.

Discovery and in Vivo Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor

Cathepsin C (Cat C) participates in inflammation and immune regulation by affecting the activation of neutrophil serine proteases (NSPs). Therefore, cathepsin C is an attractive target for treatment of NSP-related inflammatory diseases. Here, the complete discovery process of the first potent "non-peptidyl non-covalent cathepsin C inhibitor"was described with hit finding, structure optimization, and lead discovery. Starting with hit 14, structure-based optimization and structure-activity relationship study were comprehensively carried out, and lead compound 54 was discovered as a potent drug-like cathepsin C inhibitor both in vivo and in vitro. Also, compound 54 (with cathepsin C Enz IC50 = 57.4 nM) exhibited effective anti-inflammatory activity in an animal model of chronic obstructive pulmonary disease. These results confirmed that the non-peptidyl and non-covalent derivative could be used as an effective cathepsin C inhibitor and encouraged us to continue further drug discovery on the basis of this finding.